Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02912572 |
Recruitment Status :
Active, not recruiting
First Posted : September 23, 2016
Last Update Posted : April 19, 2024
|
Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Pfizer
Information provided by (Responsible Party):
Panagiotis Konstantinopoulos, MD, PhD, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | March 2025 |
Estimated Study Completion Date : | March 2027 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):